tbuckley/cabot-search huggingface dataset:
Abstract B2-18: Mechanisms of GBM progression on bevacizumab: Model predictions
Authors: Elizabeth Scribner, Olivier Saut, Thierry Colin, Hassan M. Fathallah-Shaykh
Journal: Cancer Research (2015)

Abstract Glioblastoma multiforme (GBM) causes significant neurological morbidity and short survival times. Brain invasion by GBM is associated with poor prognosis. Recent clinical trials of bevacizumab in newly-diagnosed GBM found no beneficial effects on overall survival times. We have reported a mathematical model of GBM growth and invasion, built at the scale of clinical magnetic resonance imaging. Here, we replicate the patterns of progression of GBM patients treated with bevacizumab. The model is interrogated to derive a mechanistic explanation for each type of recurrence. Citation Format: Elizabeth Scribner, Olivier Saut, Thierry Colin, Hassan M. Fathallah-Shaykh. Mechanisms of GBM progression on bevacizumab: Model predictions. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B2-18.
Dual HER2 Blockade Slows Metastatic Breast Cancer
Authors: Eric Bender
Journal: Cancer Discovery (2011)

Abstract A combination of the anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies pertuzumab (Genentech) and trastuzumab (Herceptin; Genentech) with docetaxel has reduced risk of progression by 38% over treatment with trastuzumab and docetaxel in a study of 808 patients with HER2-positive metastatic breast cancer.
Abstract B1-11: Application of the CN-AVG method to reconstruct the evolutionary history of glioblastoma multiforme
Authors: Tracy J. Ballinger, Daniel Zerbino, Benedict Paten, David Haussler
Journal: Cancer Research (2015)

Abstract We have constructed evolutionary histories of cancer genomes using a new method, the Copy Number Ancestral Variation Graph (CN-AVG). Unlike previous cancer evolutionary studies which infer the clonal structure and evolutionary history of a tumor using single nucleotide variant frequencies, the CN-AVG method predicts the ordering of structural rearrangements, such as inversions, duplications, and deletions, using copy number changes and breakpoints derived from whole genome sequencing data. Because finding the most parsimonious ordering of genomic rearrangements is an NP hard problem, we build a consensus history by merging a large number of possible evolutionary histories generated from MCMC sampling. We tested the CN-AVG method on simulated rearranged genomes and achieved an average accuracy of 62%. We also found that accuracy decreased with increasing complexity of the simulated rearrangements, as expected. We then applied the method to TCGA Glioblastoma Multiforme genomes to search for evolutionary patterns in this disease. The CN-AVG method may distinguish driver mutations as the early rearrangement events and passenger or secondary mutations as the later events in the reconstructed evolutionary history of the tumor, and will be powerful for both the clinic and for research. Citation Format: Tracy J. Ballinger, Daniel Zerbino, Benedict Paten, David Haussler. Application of the CN-AVG method to reconstruct the evolutionary history of glioblastoma multiforme. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B1-11.
MADURA FOOT, MORE PROPERLY CALLED MYCETOMA
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of dose-modified FOLFIRINOX on toxicity and effectiveness in Japanese patients with unresectable pancreatic cancer (PC).
Authors: Kazuhiro Uesugi, Akinori Asagi, Kaori Hino, Seijin Nadano, Haruo Iguchi
Journal: Journal of Clinical Oncology (2015)

480 Background: FOLFIRINOX has been shown superior to GEM in terms of OS, PFS and/or RR for treatment of metastatic PC in Accord 11, and this regimen has become the standard of care for the first -line chemotherapy. However, the major disadvantage of FOLFIRINOX is significantly higher toxicity, and, in particular, quite higher incidence of neutropenia(78%) and febrile neutropenia(22%) was observed in the PII clinical trial of FOLFIRINOX performed in Japan (LOHP-PII-05, JSCO 2013). Thus, in clinical practice for the Japanese patients, it should be needed to make modification on this regimen in terms of dose reduction without compromising in its effectiveness. We evaluated the safety and efficacy of modified(m) FOLFIRINOX in Japanese patients with unresectable locally advanced PC(LAPC) and/or metastatic PC(MPC). Methods: The modifications to FOLFIRINOX include discontinuation of the bolus 5-FU and dose-reduction(25%) of irinotecan. 20 patients with unresectable LAPC and/or MPC (PS 0-1) were treated with m FOLFIRINOX given every 2 weeks, and toxicity and efficacy were evaluated in these patients who received more than 3 courses. All patients did not receive prophylactic filgrastim. Results: Patient characteristics were as follows: LAPC/MPC 4/9; median age 65 yrs(range 39~75); male/female 15/5. Median number of cycles was 5.5 (range 1~17). Grade 3/4 toxicities included neutropenia(25%), nausea(30%), anorexia(35%) and diarrhea(20%). Grade 1/2 toxicities were sensory neuropathy(45%) and vomiting(40%). Febrile neutropenia was noted in 2 patients(10%). Toxic death was not observed, and 12 patients(60%) required dose reduction due to toxicity. Hematologic toxicities were decreased, however, those concerned with gastrointestinal toxicities were observed in a bit higher incidence compared to those in LOHP-PII-05. Response by CA19-9 was evaluable in 11 patients. 9 of 11 patients (82%) showed a decline in CA19-9 levels from baseline, and a greater than 50% decline was noted in 5 of 11 patients(45%). Conclusions: m FOLFIRINOX seems to have an improved safety profile even without prophylactic filgrastim and to maintain its efficacy.
Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents
Authors: Christie Perelló M., Carlos Fernández-Carrillo, María-Carlota Londoño, Teresa Arias-Loste, Marta Hernández-Conde, Susana Llerena, Javier Crespo, Xavier Forns, José Luis Calleja
Journal: Clinical Gastroenterology and Hepatology (2016)
Effects of early leucovorin rescue.
Authors: J S Holcenberg
Journal: Journal of Clinical Oncology (1984)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1984.2.9.1072 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 6332179 Effects of early leucovorin rescue. J S HolcenbergxJ S HolcenbergSearch for articles by this author https://doi.org/10.1200/JCO.1984.2.9.1072 PDF "Effects of early leucovorin rescue.." Journal of Clinical Oncology, 2(9), p. 1072© 1984 by American Society of Clinical Oncology
Phospho-mTOR expression levels, proliferative acitivity (Ki67) and pancreatic primary tumor may influence the response to everolimus in neuroendocrine tumor patients: results from an Italian preliminary study
Authors: N. Birocco, M.P. Brizzi, M. Airoldi, C. De Angelis, F. Maletta, A. Piovesan, I. Rapa, A. Sapino, M. Scaldaferri, G. Scagliotti, M. Papotti, M. Volante
Journal: Annals of Oncology (2015)
West Nile virus: the Italian national transplant network reaction to an alert in the north-eastern region, Italy 2011
Authors: A Nanni Costa, M R Capobianchi, G Ippolito, G Palù, L Barzon, G Piccolo, B Andreetta, M Filippetti, D Fehily, L Lombardini, P Grossi
Journal: Eurosurveillance (2011)

We report four cases of West Nile virus (WNV) transmission following a single multiorgan donation in north-eastern Italy. The transmissions were promptly detected by local transplant centres. The donor had been tested for WNV by nucleic acid amplification test (NAT) prior to transplantation and was negative. There were no detected errors in the nationally implemented WNV safety protocols.
Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer
Authors: B Xu, F Ma, S Chen, Q Li, F Yang, Y Zhang, X Chen, D Zhong, G Zhang
Journal: Cancer Research (2016)

Abstract Pyrotinib is a novel small molecule irreversible pan-ErbB receptor tyrosine kinase inhibitor. This phase I study was designed to evaluate the safety, pharmacokinetics and antitumor activity of pyrotinib in Chinese patients with ErbB2+ metastatic breast cancer (n=38). The majority of patients were previously treated with multiple lines (≤5) of anti-tumor regimens including trastuzumab. The dose-escalation study was conducted at 80, 160, 240, 320, 400 and 480 mg levels in patients receiving oral pyrotinib with food once daily on a 28-day cycle. Dose-limiting toxicity (DLT) was grade 3 diarrhea, which occurred in two out of two patients treated with 480mg pyrotinib during the dose-escalation. Therefore, the maximum tolerated dose (MTD) of pyrotinib was determined to be 400 mg per day. In general, pyrotinib was safe and well tolerated when administered to patients. The majority of adverse events which occurred in the study were grade I and II. The pharmacokinetic results showed linear characteristics along the range of doses tested, and supports a once daily dosing regimen. The overall objective response rate (ORR) was 52.8% and disease control rate (DCR) was 80.6% in 36 patients (19 PR and 10 SD), with the highest ORR of 55.6% (5/9) and 87.5% (7/8) observed in 320 mg and 400 mg cohorts, respectively. The median duration of response was 32.3 weeks. In addition, 3 (8.3%) subjects achieved stable disease for at least 24 weeks. Kaplan-Meier median progression-free survival (PFS) was 35.3 weeks (95%CI: 23.6∼39.9 weeks) among all subjects treated with 80-400 mg, and the median PFS for 320 mg and 400 mg cohorts was 39.9 weeks (95%CI: 31.1∼47.4 weeks). Based on tolerability, safety, PK and efficacy data of 6 dose-cohorts, 320 mg and 400mg of pyrotinib once daily could be considered a recommended regimen for Phase II studies. The promising antitumor activity of pyrotinib observed in patients with ErbB2+ metastatic breast cancer, who had previous treatment with anthracyclines, taxanes, and trastuzumab, warrants its further study (ClinicalTrials.gov number, NCT01937689). Citation Format: Xu B, Ma F, Chen S, Li Q, Yang F, Zhang Y, Chen X, Zhong D, Zhang G. Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-18.
A neural-network interpretation of selection in learning and behavior
Authors: José E Burgos
Journal: Behavioral and Brain Sciences (2001)

In their account of learning and behavior, the authors define an interactor as emitted behavior that operates on the environment, which excludes Pavlovian learning. A unified neural-network account of the operant-Pavlovian dichotomy favors interpreting neurons as interactors and synaptic efficacies as replicators. The latter interpretation implies that single-synapse change is inherently Lamarckian.
Evidence-Based Guideline: CHEST made 20 strong recommendations about antithrombotic therapy for VTE
Authors: Richard H. White
Journal: Annals of Internal Medicine (2016)

ACP Journal Club17 May 2016Evidence-Based Guideline: CHEST made 20 strong recommendations about antithrombotic therapy for VTERichard H. White, MDRichard H. White, MDUniversity of California Davis, Sacramento, California, USA (R.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-164-10-052 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationKearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-52. https://pubmed.ncbi.nlm.nih.gov/26867832Clinical Impact RatingsGIM/FP/GP: Hematology: Author, Article, and Disclosure InformationAffiliations: University of California Davis, Sacramento, California, USA (R.H.W.)This article was published at Annals.org on 3 May 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 May 2016Volume 164, Issue 10Page: JC52KeywordsAnticoagulantsDeep vein thrombosisMedical risk factorsPatient advocacyPulmonary embolismSystematic reviewsThoraxTreatment guidelinesVeinsVenous thromboembolism ePublished: 17 May 2016 Issue Published: 17 May 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract A03: Inhibition of the histone/protein acetyltransferase, Tip60, impairs Foxp3 acetylation and Treg function and thereby promotes antitumor immunity
Authors: Wayne W. Hancock, Liqing Wang, Kheng Newick, Aaron Beeler, Steven M. Albelda
Journal: Cancer Research (2016)

Abstract Although the important role of Foxp3+ Tregs in suppressing immune responses to solid tumors is well accepted, to date, there has been little success in targeting this population other than by their transient depletion or “secondary” modulation by mAbs to CTLA-4. In contrast, we have undertaken a mechanism-driven approach to Treg targeting based on our ongoing research into the post-translational modifications that regulate Foxp3, such as its acetylation by one or more histone/protein acetyltransferase (HAT) enzymes. Our analysis of each of the main HAT families has shown that members of the Myst family have the greatest contribution, with Tip60 deletion leading to lethal autoimmunity within 3 weeks of birth. We have now translated these insights into the development and testing of a new pharmacologic inhibitor of Tip60 (Tip60i) that binds to the Ac-CoA site of Tip60. First, submicromolar levels of this Tip60i impaired Treg function in vitro but preserved conventional T cell proliferation. Second, Tip60 administration in vivo (10 mg/kg/d, 14 d) revoked Treg-dependent allograft tolerance induced by CD40L mAb plus donor splenocyte transfusion, and restored T cell-dependent cardiac allograft rejection. These studies illustrate the ability of the Tip60i to impair Treg functions while preserving protective effector T cell functions. Third, treatment of immunocompetent mice bearing established TC1 lung adenocarcinomas (which we have shown is a Treg-sensitive tumor) with Tip60i (1 mg/kg/d) significantly impaired tumor growth (p&amp;lt;0.001). While further medicinal chemistry of this compound is underway, including modification with phthalimide tags, our data provide the crucial first evidence that Tip60 is a druggable and potent target for modulation of Foxp3+ Treg function in vitro and in vivo, and show that Tip60 inhibition can enhance host anti-tumor immunity. Citation Format: Wayne W. Hancock, Liqing Wang, Kheng Newick, Aaron Beeler, Steven M. Albelda. Inhibition of the histone/protein acetyltransferase, Tip60, impairs Foxp3 acetylation and Treg function and thereby promotes antitumor immunity. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr A03.
PARE0015 How the Swedish Rheumatism Association Work to Increase Research on Osteoarthritis
Authors: K. Blidberg, A. Carlsson
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Osteoarthritis is a common disease. New studies show that as many as 25% of the Swedish population older than 45 years may be affected<sup>1</sup>. In spite of this there is little research in the area and among both general practitioners and the public the knowledge of the disease is limited. Osteoarthritis is often viewed as a result of wear and tear and old age and something the patient just needs to accept rather than the treatable disease it is. <h3>Objectives</h3> The Swedish Rheumatism Association has observed a lack of awareness of the magnitude of osteoarthritis problem and a decision was made to try and increase the interest for research in this area. <h3>Methods</h3> The Swedish Rheumatism Association invited researchers, decision makers, and research foundations to an osteoarthritis forum. The objective of the meeting was to identify problem areas and how research within the osteoarthritis field could be encouraged. Following the osteoarthritis forum the Swedish Rheumatism Association opened a call for research on osteoarthritis. <h3>Results</h3> The call received 30 applications. The applications were reviewed by a group of experts and total of 1.5 million Swedish krona were distributed between nine projects. The awarded projects span from basic research on biomarkers and disease mechanisms to studies of more epidemiological character on the natural course of knee osteoarthritis and patient perceived benefits of a supported osteoarthritis self-management program. In addition to this, a position for an associated professor was co-founded by the Swedish Rheumatism Association. <h3>Conclusions</h3> In order to gather the available potential for qualified osteoarthritis research there is a need to focus on osteoarthritis as an entity of its own. The research fund of Swedish Rheumatism Association distribute relatively small research grants, however, by taking the initiative to focus on osteoarthritis they can challenge and encourage other to follow their initiative. An additional benefit of supporting osteoarthritis research is that increased research may also improve the status of osteoarthritis as a diagnosis. There is a growing awareness among the public of osteoarthritis. This is displayed as a massive interest in open lectures on osteoarthritis but also as headlines and articles in both the daily and weekly press. The special focus on osteoarthritis research will continue the next few years. In addition to the use of money from the research fund of the Swedish Rheumatism Association the association also works to encourage other organisations that fund research to lift osteoarthritis to their agenda. <h3>References</h3> Turkiewicz A, Gerhardsson de Verdier M, Engström G, Nilsson PM, Mellström C, Lohmander LS, Englund M. Prevalence of knee pain and knee OA in southern Sweden and the proportion that seeks medical care. Rheumatology 2014 Oct 13. <h3>Disclosure of Interest</h3> None declared
AB0357 Does the Body Mass Index (BMI) Influence the Clinical Assessment of Synovitis in Rheumatoid Arthritis?
Authors: J. Goossens, S. Ottaviani, B. Coustet, E. Palazzo, P. Dieudé
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> It was suggested that obesity and adipose tissue could play a role in the course of rheumatoid arthritis (RA). Obesity, defined by a BMI ≥30 kg/m<sup>2</sup>, is associated in some studies with increased risk of RA and might have a protective effect early during the disease. Obesity could also be associated with more severe functional and pain outcomes. Regarding this excess adipose tissue and more pain score in obese patient, it could be speculated that clinical assessment of swollen joint count and RA disease activity measurement might be affected by obesity. <h3>Objectives</h3> The aim of the study was to assess the influence of BMI on clinical RA disease activity assessment by clinical exam in comparison with ultrasound (US). <h3>Methods</h3> A total of 76 RA patients, fulfilled the ACR/EULAR criteria for RA, were included in this single-center transversal study. The following data were collected: BMI; gender; age; disease duration; disease activity score in 28 joints (DAS28); pain on a visual analog scale (VAS, 0-100 mm); tender joint count (TJC) and swollen joint count (SJC) in 28 sites; anti-CCP antibodies and rheumatoid factor (RF) status; erosive status; use of disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids or previous biologic agents; erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP) level. BMI was calculated as weight in kilograms divided by height in square meters. According to the World Health Organization criteria, normal BMI was defined as &lt;25 kg/m<sup>2</sup>, overweight 25-30 kg/m<sup>2</sup>, and obesity ≥30 kg/m<sup>2</sup>. US assessment was performed the same day by one rheumatologist blinded to clinical data. An US SJC on 28 sites was measured for each patient. US synovitis was defined as a grey scale score ≥2 and/or Power Doppler ≥1. The primary outcome measure was the delta synovitis between clinical SJC and US SJC. Secondary outcomes were the delta DAS28 and the proportion of patient in Eular remission. <h3>Results</h3> The distribution of patients with normal weight, overweight and obesity was 29 (38.2%), 33 (43.4%)and 14 (18.4%), respectively. The mean age was 53.8±11.8 years (51 (77%) of female). The mean disease duration was 12.3±9.2 years. Baseline characteristics did not differ between the three subgroups of BMI. In absolute values, the mean delta synovitis counts between US and clinical exam were not statistically different among normal weight (2.1), overweight (2.2) and obese patients (2.2). The delta (US – clinical exam) DAS28 was not modified in obese patients in comparison with other BMI subgroups. Finally, using US synovitis joint count in comparison with clinical exam assessment, did not affect the proportion of patients in Eular remission. <h3>Conclusions</h3> BMI and particularly obesity do not influence the swollen joint count and disease activity measurement. <h3>Disclosure of Interest</h3> None declared
18F-FDG PET/CT of Widespread Rosai-Dorfman Disease
Authors: Varun Singh Dhull, Averlicia Passah, Neelima Rana, Kavneet Kaur, Madhavi Tripathi, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2015)

We present a rare case of Rosai-Dorfman disease who was sent for whole-body 18F-FDG PET/CT to know the exact extent of involvement. PET/CT revealed extensive nodal and extranodal involvement from head to toe including osteolytic lesions in metacarpals, metatarsals, and phalanges. It is important to know the exact extent of the disease as this may alter the patient management.